Mode
Text Size
Log in / Sign up
N/A N=136 Randomized Double-blind Other

Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors

Tobacco Addiction · Dual Tobacco Use

Enrolled (actual)
136
Serious AEs
0.7%
Results posted
Mar 2017
Primary outcome: Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
VLNC cigarettes (Other); Combusted Products (Other); Non-combusted products (Other); CN cigarettes (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Minnesota
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Days Using Alternative Products
14; 26; 20
PRIMARY
Number of Combusted Products Smoked
19.2; 12.9; 13.5
SECONDARY
Rate of 24 Hour Quit Attempts
2; 12; 15
SECONDARY
Carcinogen Exposure Biomarker: Total NNAL
1.22; 0.71; 0.51

Summary

The main focus of this study is to determine the use of nicotine-containing products across the three experimental conditions. Subjects will be monitored to determine their continued use of assigned cigarettes, switching to other combusted and/or non-combusted tobacco, or cessation of all tobacco containing products.

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects who are at least 18 years of age with a history of regular smoking for at least 1 year and no serious quit attempts in the last 3 months
  • No unstable and significant medical or psychiatric conditions, including lack of stabilization of medications.
  • Subject has provided written informed consent to participate in the study

Exclusion Criteria

  • Regular use of tobacco products (including e-cigarettes) other than cigarettes
  • Regular use of nicotine replacement or other tobacco cessation products for purpose of quitting.
  • Pregnant or breastfeeding (due to toxic effects from tobacco products).
  • Planned quit date within the next two months.
  • Does not have a way that the research team can communicate with them by phone or e-mail.
  • Not able to read and write English well enough to complete study activities without translation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02000921). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search